Overview

A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)

Status:
RECRUITING

Trial end date:
2026-07-03

Target enrollment:

Participant gender:

Summary

This was an open-label, randomized, fasting, single-dose, 2-sequence, 2-period crossover study to evaluate the pharmacokinetics and safety between single oral administration of "BR3006" and co-administration of "BR3006A", "BR3006B," and "BR3006C" in healthy adult volunteers.

Phase:

PHASE1

Details

Lead Sponsor:

Boryung Pharmaceutical Co., Ltd

Treatments:

dapagliflozin
Metformin
Pioglitazone